全文获取类型
收费全文 | 1824788篇 |
免费 | 128549篇 |
国内免费 | 4230篇 |
专业分类
耳鼻咽喉 | 24051篇 |
儿科学 | 59210篇 |
妇产科学 | 49234篇 |
基础医学 | 258436篇 |
口腔科学 | 53523篇 |
临床医学 | 159619篇 |
内科学 | 364818篇 |
皮肤病学 | 42784篇 |
神经病学 | 141739篇 |
特种医学 | 66736篇 |
外国民族医学 | 244篇 |
外科学 | 272522篇 |
综合类 | 39776篇 |
现状与发展 | 4篇 |
一般理论 | 571篇 |
预防医学 | 137126篇 |
眼科学 | 42965篇 |
药学 | 132672篇 |
7篇 | |
中国医学 | 5183篇 |
肿瘤学 | 106347篇 |
出版年
2021年 | 16370篇 |
2019年 | 16857篇 |
2018年 | 24594篇 |
2017年 | 17987篇 |
2016年 | 19312篇 |
2015年 | 21963篇 |
2014年 | 30304篇 |
2013年 | 43816篇 |
2012年 | 61849篇 |
2011年 | 65253篇 |
2010年 | 37989篇 |
2009年 | 34767篇 |
2008年 | 58982篇 |
2007年 | 62645篇 |
2006年 | 62570篇 |
2005年 | 59844篇 |
2004年 | 57215篇 |
2003年 | 54178篇 |
2002年 | 51955篇 |
2001年 | 95074篇 |
2000年 | 97343篇 |
1999年 | 79901篇 |
1998年 | 20406篇 |
1997年 | 17816篇 |
1996年 | 17840篇 |
1995年 | 17126篇 |
1994年 | 15614篇 |
1993年 | 14335篇 |
1992年 | 58549篇 |
1991年 | 56277篇 |
1990年 | 53861篇 |
1989年 | 51495篇 |
1988年 | 46786篇 |
1987年 | 45537篇 |
1986年 | 42846篇 |
1985年 | 40519篇 |
1984年 | 29739篇 |
1983年 | 25226篇 |
1982年 | 14106篇 |
1979年 | 25899篇 |
1978年 | 17835篇 |
1977年 | 15101篇 |
1976年 | 14081篇 |
1975年 | 14835篇 |
1974年 | 17972篇 |
1973年 | 17284篇 |
1972年 | 15956篇 |
1971年 | 14773篇 |
1970年 | 13707篇 |
1969年 | 12810篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
Mohid S Khan Thomas Walter Amy Buchanan-Hughes Emma Worthington Lucie Keeber Marion Feuilly Enrique Grande 《World journal of gastroenterology : WJG》2020,26(30):4537-4556
BACKGROUND Approximately 20% of patients with neuroendocrine tumours(NETs) develop carcinoid syndrome(CS),characterised by flushing and diarrhoea.Somatostatin analogues or telotristat can be used to control symptoms of CS through inhibition of serotonin secretion.Although CS is often the cause of diarrhoea among patients with gastroenteropancreatic NETs(GEP-NETs),other causes to consider include pancreatic enzyme insufficiency(PEI),bile acid malabsorption and small intestinal bacterial overgrowth.If other causes of diarrhoea unrelated to serotonin secretion are mistaken for CS diarrhoea,these treatments may be ineffective against the diarrhoea,risking detrimental effects to patient quality of life.AIM To identify and synthesise qualitative and quantitative evidence relating to the differential diagnosis of diarrhoea in patients with GEP-NETs.METHODS Electronic databases(MEDLINE,Embase and the Cochrane Library) were searched from inception to September 12,2018 using terms for NETs and diarrhoea.Congresses,systematic literature review bibliographies and included articles were also hand-searched.Any study designs and publication types were eligible for inclusion if relevant data on a cause(s) of diarrhoea in patients with GEP-NETs were reported.Studies were screened by two independent reviewers at abstract and full-text stages.Framework synthesis was adapted to synthesise quantitative and qualitative data.The definition of qualitative data was expanded to include all textual data in any section of relevant publications.RESULTS Forty-seven publications(44 studies) were included,comprising a variety of publication types,including observational studies,reviews,guidelines,case reports,interventional studies,and opinion pieces.Most reported on PEI on/after treatment with somatostatin analogs;9.5%-84% of patients with GEP-NETs had experienced steatorrhoea or confirmed PEI.Where reported,14.3%–50.7% of patients received pancreatic enzyme replacement therapy.Other causes of diarrhoea reported in patients with GEP-NETs included bile acid malabsorption(80%),small intestinal bacterial overgrowth(23.6%-62%),colitis(20%) and infection(7.1%).Diagnostic approaches included faecal elastase,breath tests,tauroselcholic(selenium-75) acid(Se HCAT) scan and stool culture,although evidence on the effectiveness or diagnostic accuracy of these approaches was limited.Assessment of patient history or diarrhoea characteristics was also reported as initial approaches for investigation.From the identified evidence,if diarrhoea is assumed to be CS diarrhoea,consequences include uncontrolled diarrhoea,malnutrition,and perceived ineffectiveness of CS treatment.Approaches for facilitating differential diagnosis of diarrhoea include improving patient and clinician awareness of non-CS causes and involvement of a multidisciplinary clinical team,including gastroenterologists.CONCLUSION Diarrhoea in GEP-NETs can be multifactorial with misdiagnosis leading to delayed patient recovery and inefficient resource use.This systematic literature review highlights gaps for further research on prevalence of non-CS diarrhoea and suitability of diagnostic approaches,to determine an effective algorithm for differential diagnosis of GEP-NET diarrhoea. 相似文献
22.
Stepanova E. S. Makarenkova L. M. Chistyakov V. V. Rybakov Yu. L. Gukasov V. M. Fedotcheva T. A. Parshin V. A. Votyakov V. A. Shimanovskii N. L. 《Pharmaceutical Chemistry Journal》2019,52(12):1016-1020
Pharmaceutical Chemistry Journal - An HPLC-MS method for simultaneous quantitative determination of a novel gestagenic pharmaceutical and two of its metabolites in rat and rabbit blood sera was... 相似文献
23.
24.
目的 对血清甲状腺球蛋白免疫复合物 (thyroglobulin circulating immune complex, Tg-CIC) 中抗甲状腺球蛋白抗体 (anti-thyroglobulin antibody, Tg-Ab) 含量检测,探讨 Tg-CIC 在甲状腺疾病中的临床以及流行病学意义。方法 收集甲状腺疾病患者血清标本 187 例,每例血清标本分为两组 ( 实验组和空白对照组 ),采用免疫复合物解离专利技术对甲状腺疾病患者血清标本 Tg-CIC 进行分离、解离,通过检测 Tg-CIC 解离后的 Tg-Ab 含量来间接反映甲状腺疾病患者血清中Tg-CIC 水平,按照不同的甲状腺疾病进行分组并对实验结果分析讨论。结果 不同甲状腺患者血清中 Tg-CIC 总阳性率达 92.51%,不同甲状腺疾病血清中 Tg-CIC 的阳性率差异无统计学意义 (χ?=2.917, P>0.05)。不同甲状腺疾病患者间血清游离 Tg-Ab 含量差异无统计学意义 (H=3.882, P>0.05),不同甲状腺疾病患者间血清 CIC 中 Tg-Ab 含量差异无统计学意义(H=5.5842, P>0.05)。不同甲状腺疾病患者中,甲状腺功能亢进、甲状腺炎以及甲状腺结节患者血清游离 Tg-Ab 的含量与血清 CIC 中的 Tg-Ab 含量呈正相关 (P<0.05),甲状腺功能减退、甲状腺肿瘤患者血清游离 Tg-Ab 的含量与血清 CIC 中的Tg-Ab 含量不相关 (P>0.05)。结论 在甲状腺疾病患者血清中,大部分可检出 Tg-CIC,与疾病类型无关。而甲状腺疾病患者中,甲状腺功能亢进、甲状腺炎以及甲状腺结节患者血清游离 Tg-Ab 含量与血清 CIC 中 Tg-Ab 含量存在相关性,为我们进一步了解 Tg-CIC 与甲状腺疾病的发生、发展的相关性研究奠定了基础,提供了新的研究视角。 相似文献
25.
26.
27.
Ali Mobasheri Csaba Matta Ilona Uzielienè Emma Budd Pablo Martín-Vasallo Eiva Bernotiene 《Joint, bone, spine : revue du rhumatisme》2019,86(1):29-35
Chondrocytes are the main cells in the extracellular matrix (ECM) of articular cartilage and possess a highly differentiated phenotype that is the hallmark of the unique physiological functions of this specialised load-bearing connective tissue. The plasma membrane of articular chondrocytes contains a rich and diverse complement of membrane proteins, known as the membranome, which defines the cell surface phenotype of the cells. The membranome is a key target of pharmacological agents and is important for chondrocyte function. It includes channels, transporters, enzymes, receptors, and anchors for intracellular, cytoskeletal and ECM proteins and other macromolecular complexes. The chondrocyte channelome is a sub-compartment of the membranome and includes a complete set of ion channels and porins expressed in these cells. Many of these are multi-functional proteins with “moonlighting” roles, serving as channels, receptors and signalling components of larger molecular assemblies. The aim of this review is to summarise our current knowledge of the fundamental aspects of the chondrocyte channelome, discuss its relevance to cartilage biology and highlight its possible role in the pathogenesis of osteoarthritis (OA). Excessive and inappropriate mechanical loads, an inflammatory micro-environment, alternative splicing of channel components or accumulation of basic calcium phosphate crystals can result in an altered chondrocyte channelome impairing its function. Alterations in Ca2+ signalling may lead to defective synthesis of ECM macromolecules and aggravated catabolic responses in chondrocytes, which is an important and relatively unexplored aspect of the complex and poorly understood mechanism of OA development. 相似文献
28.
29.